Doxycycline Use During Breastfeeding
Primary Recommendation
- The American Academy of Dermatology recommends limiting oral doxycycline use to 3 weeks maximum without repeating courses for breastfeeding patients requiring systemic antibiotics, representing a high-quality guideline consensus from 2025 1, 2
Safety Evidence Supporting Use
- The European Respiratory Society and the American Academy of Dermatology suggest that short-term use of doxycycline by lactating women is acceptable due to low concentrations in breast milk and potential inhibition of infant absorption by calcium in breast milk 3, 1
Duration Limits and Key Restrictions
- The maximum treatment duration with doxycycline is recommended to be 3-4 weeks, with avoidance of repeated courses, as suggested by the European Respiratory Journal and the Journal of the American Academy of Dermatology 3, 1, 2
Clinical Decision Algorithm
- Doxycycline can be used when short-term treatment (≤3 weeks) is sufficient, alternative safer antibiotics are inadequate or unavailable, and the infant is healthy, full-term, and not premature, as recommended by the European Respiratory Journal and the Journal of the American Academy of Dermatology 3, 1
- Doxycycline should be avoided when treatment would require >3-4 weeks, repeated courses would be necessary, the infant is premature, jaundiced, or has a condition that may be affected by the drug, or safer alternatives are available, as suggested by the European Respiratory Journal and the Journal of the American Academy of Dermatology 3, 1, 2
Preferred Alternative Antibiotics During Breastfeeding
- The Journal of the American Academy of Dermatology suggests amoxicillin/clavulanic acid, erythromycin or azithromycin, and metronidazole as first-line alternative antibiotics with stronger safety profiles during breastfeeding 3, 1, 2
- Clindamycin should be used with caution due to potential increased risk of GI side effects in the infant, as noted by the Journal of the American Academy of Dermatology 1, 2
Important Caveats
- The British Thoracic Society guidelines from 2017 listed breastfeeding as a contraindication for doxycycline, but this has been superseded by more recent guidelines from the Journal of the American Academy of Dermatology in 2025, which suggest short-term use is acceptable 1, 2, 4, 5
Doxycycline Safety in Nursing Mothers
Safety Profile in Lactation
- The American Academy of Pediatrics Committee on Drugs lists tetracycline as "usually compatible with breastfeeding" 6
- Tetracyclines, including doxycycline, are present only in very low levels in breast milk, and calcium in breast milk might inhibit absorption by infants 7
Clinical Evidence Supporting Safety
- One study of mothers on a steady state dose of tetracycline found that it reached a peak breast milk concentration of only a low level and was undetectable in the serum of their breastfeeding infants 7
- Because of the low concentrations of all tetracyclines found in breast milk, significant adverse reactions in nursing infants are unlikely 7
- Doxycycline is now considered acceptable for short-term use even in children aged under 8 years, which further supports its safety profile during breastfeeding 7
Recommendations for Use
- Doxycycline should only be prescribed for short-term use with avoidance of repeated courses in nursing mothers 7
Special Considerations
- If a nursing mother requires tetracycline treatment, doxycycline may be preferred over other tetracyclines due to its better safety profile 7
- For life-threatening conditions, the benefits of doxycycline treatment clearly outweigh potential risks 6
Alternative Antibiotics
- Fluoroquinolones are present in breast milk in quantities far below the usual pediatric dosage 7
- Aminoglycosides are poorly absorbed by the gastrointestinal tract and present in breast milk in very low quantities 7
- Trimethoprim-sulfamethoxazole is found in very low levels in breast milk but should be avoided in infants with certain pre-existing conditions 7
Doxycycline Use in Breastfeeding: Evidence‑Based Recommendations
Guideline Consensus
The American Academy of Pediatrics Committee on Drugs considers tetracyclines (including doxycycline) “usually compatible with breastfeeding,” and the FDA label states that short‑term use by lactating women is not necessarily contraindicated. 8
The Centers for Disease Control and Prevention (CDC) MMWR Recommendations (2016) advise that for life‑threatening tick‑borne rickettsial diseases (e.g., Rocky Mountain spotted fever, ehrlichiosis, anaplasmosis), doxycycline should be administered regardless of breastfeeding status because delayed therapy can lead to severe disease or death. 8
Safety Evidence from Clinical Cases
A 2006 case series reported successful treatment of a pregnant woman with human granulocytic anaplasmosis and her newborn using doxycycline, with no adverse effects observed in the infant. 9
A 2006 case report described a postpartum mother who received doxycycline for two weeks while breastfeeding; follow‑up showed both mother and infant remained well without complications. 9